AGIO logo

AGIO
Agios Pharmaceuticals Inc

2,917
Mkt Cap
$1.67B
Volume
874,516.00
52W High
$46.00
52W Low
$22.24
PE Ratio
-3.88
AGIO Fundamentals
Price
$28.14
Prev Close
$28.79
Open
$28.69
50D MA
$29.47
Beta
1.09
Avg. Volume
1.38M
EPS (Annual)
-$7.12
P/B
1.51
Rev/Employee
$100,051.85
$763.78
Loading...
Loading...
News
all
press releases
Avanzanite Biosciences Partner Agios Announces PYRUKYND (mitapivat) Approval in the European Union for Adults with Thalassaemia
Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts...
News Placeholder
More News
News Placeholder
Agios Seeks FDA Nod to Expand Mitapivat Label in Sickle Cell Disease
AGIO seeks FDA accelerated approval for mitapivat in sickle cell disease after mixed phase III data and a planned confirmatory study.
News Placeholder
Agios Files FDA Application Seeking Accelerated Approval Of Mitapivat For Sickle Cell Disease
(RTTNews) - Rare disease drugmaker Agios Pharmaceuticals Inc. (AGIO) on Tuesday announced the submission of a supplemental New Drug Application, or sNDA, to the U.S. Food and Drug Administration...
News Placeholder
HC Wainwright Issues Positive Outlook for AGIO Earnings
Agios Pharmaceuticals, Inc. (NASDAQ:AGIO - Free Report) - Stock analysts at HC Wainwright raised their Q2 2026 earnings per share (EPS) estimates for Agios Pharmaceuticals in a research note issued on Wednesday, April 29th. HC Wainwright analyst E. Bodnar now expects that the biopharmaceutical compa...
News Placeholder
Here's Why Shares in Agios Pharmaceuticals Soared This Week (And What to Expect Next in 2026)
Key PointsAgios shares rose after strong earnings and Aqvesme's commercial launch...
News Placeholder
AGIO Beats on Q1 Earnings & Sales, Stock Up 13% on New Drug Momentum
Agios shares jump 13% as Q1 revenues surge 138% on Aqvesme launch and Pyrukynd growth, while pipeline advances and SCD filing plans take shape.
News Placeholder
Truist Financial Issues Pessimistic Forecast for Agios Pharmaceuticals (NASDAQ:AGIO) Stock Price
Truist Financial decreased their target price on shares of Agios Pharmaceuticals from $39.00 to $36.00 and set a "buy" rating for the company in a research note on Thursday...
News Placeholder
Why Agios Pharmaceuticals Stock Zoomed to a 13% Gain on Wednesday
Key PointsIt brought in nearly $21 million in the first quarter...
News Placeholder
Agios Pharmaceuticals (NASDAQ:AGIO) Issues Quarterly Earnings Results
Agios Pharmaceuticals (NASDAQ:AGIO - Get Free Report) released its quarterly earnings results on Wednesday. The biopharmaceutical company reported ($1.69) earnings per share (EPS) for the quarter...
News Placeholder
Agios Pharmaceuticals (NASDAQ:AGIO) Shares Gap Up on Earnings Beat
Agios Pharmaceuticals (NASDAQ:AGIO) Shares Gap Up Following Earnings Beat...
<
1
2
...
>

Compact View

Mini-Chart
Sentiment
Not available
Message Volume
Not available